JP2020183440A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020183440A5 JP2020183440A5 JP2020127877A JP2020127877A JP2020183440A5 JP 2020183440 A5 JP2020183440 A5 JP 2020183440A5 JP 2020127877 A JP2020127877 A JP 2020127877A JP 2020127877 A JP2020127877 A JP 2020127877A JP 2020183440 A5 JP2020183440 A5 JP 2020183440A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- dose
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 30
- 206010028980 Neoplasm Diseases 0.000 claims 18
- 201000011510 cancer Diseases 0.000 claims 14
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims 9
- 235000017471 coenzyme Q10 Nutrition 0.000 claims 9
- 229940110767 coenzyme Q10 Drugs 0.000 claims 9
- 238000009104 chemotherapy regimen Methods 0.000 claims 8
- -1 coenzyme Q10 (CoQ10) compound Chemical class 0.000 claims 6
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical class COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 206010039491 Sarcoma Diseases 0.000 claims 4
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 208000029742 colonic neoplasm Diseases 0.000 claims 2
- 231100000371 dose-limiting toxicity Toxicity 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000005243 Chondrosarcoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010070308 Refractory cancer Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000034254 Squamous cell carcinoma of the cervix uteri Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 229940009456 adriamycin Drugs 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 201000010897 colon adenocarcinoma Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000006185 dispersion Substances 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 230000003352 fibrogenic effect Effects 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229940020967 gemzar Drugs 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 230000014207 opsonization Effects 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 claims 1
- 208000010485 smooth muscle tumor Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000002437 synoviocyte Anatomy 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 208000037965 uterine sarcoma Diseases 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261654245P | 2012-06-01 | 2012-06-01 | |
| US61/654,245 | 2012-06-01 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018109093A Division JP2018168164A (ja) | 2012-06-01 | 2018-06-07 | コエンザイムｑ１０を用いた固形腫瘍の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020183440A JP2020183440A (ja) | 2020-11-12 |
| JP2020183440A5 true JP2020183440A5 (https=) | 2020-12-24 |
| JP7225167B2 JP7225167B2 (ja) | 2023-02-20 |
Family
ID=49673946
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015515272A Active JP6352905B2 (ja) | 2012-06-01 | 2013-05-31 | コエンザイムｑ１０を用いた固形腫瘍の治療 |
| JP2018109093A Withdrawn JP2018168164A (ja) | 2012-06-01 | 2018-06-07 | コエンザイムｑ１０を用いた固形腫瘍の治療 |
| JP2020127877A Active JP7225167B2 (ja) | 2012-06-01 | 2020-07-29 | コエンザイムｑ１０を用いた固形腫瘍の治療 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015515272A Active JP6352905B2 (ja) | 2012-06-01 | 2013-05-31 | コエンザイムｑ１０を用いた固形腫瘍の治療 |
| JP2018109093A Withdrawn JP2018168164A (ja) | 2012-06-01 | 2018-06-07 | コエンザイムｑ１０を用いた固形腫瘍の治療 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20140017317A1 (https=) |
| EP (1) | EP2854528B8 (https=) |
| JP (3) | JP6352905B2 (https=) |
| KR (2) | KR20200118233A (https=) |
| CN (1) | CN104507308A (https=) |
| AU (2) | AU2013267166A1 (https=) |
| BR (1) | BR112014029954A2 (https=) |
| CA (2) | CA3090268A1 (https=) |
| EA (1) | EA032345B1 (https=) |
| ES (1) | ES2761449T3 (https=) |
| IL (1) | IL236008B (https=) |
| IN (1) | IN2014DN10734A (https=) |
| MX (2) | MX369768B (https=) |
| NZ (1) | NZ702369A (https=) |
| SG (1) | SG11201407880QA (https=) |
| WO (1) | WO2013181639A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010247800A1 (en) | 2009-05-11 | 2011-12-15 | Berg Llc | Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| CA2832324C (en) | 2011-04-04 | 2022-03-15 | Berg Llc | Methods of treating central nervous system tumors |
| MX369768B (es) * | 2012-06-01 | 2019-11-21 | Berg Llc | Composición farmacéutica de coenzima q10 para usarse en un método para tratar cáncer. |
| SG10201903112WA (en) * | 2013-04-08 | 2019-05-30 | Berg Llc | Treatment of cancer using coenzyme q10 combination therapies |
| KR102370843B1 (ko) | 2013-09-04 | 2022-03-04 | 버그 엘엘씨 | 코엔자임 q10의 연속주입에 의한 암치료 방법 |
| US9996463B2 (en) * | 2015-11-10 | 2018-06-12 | International Business Machines Corporation | Selection and placement of volumes in a storage system using stripes |
| WO2017087576A1 (en) | 2015-11-16 | 2017-05-26 | Berg Llc | Methods of treatment of temozolomide-resistant glioma using coenzyme q10 |
| US20170255565A1 (en) * | 2016-03-02 | 2017-09-07 | Intel Corporation | Method and apparatus for providing a contiguously addressable memory region by remapping an address space |
| US20200093751A1 (en) * | 2016-06-28 | 2020-03-26 | Der-Yang Tien | Chemoprotective/chemoactive nanodroplets and methods of use thereof |
| DK3634391T3 (da) * | 2017-05-17 | 2025-03-31 | Bpgbio Inc | Anvendelse af coenzym q10-formuleringer i behandlingen og forebyggelsen af epidermolysis bullosa |
| WO2023099436A1 (en) * | 2021-12-01 | 2023-06-08 | Gambro Lundia Ab | New dialysis fluid |
| WO2025087731A1 (en) * | 2023-10-24 | 2025-05-01 | Gambro Lundia Ab | Compositions comprising insulin and ketones bodies to treat cancer |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US20070104688A1 (en) | 2003-02-13 | 2007-05-10 | City Of Hope | Small interfering RNA mediated transcriptional gene silencing in mammalian cells |
| WO2005048925A2 (en) * | 2003-11-14 | 2005-06-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treating a neoplastic disease in a subject using inorganic selenium-containing compounds |
| ES2809302T3 (es) * | 2004-01-22 | 2021-03-03 | Univ Miami | Formulaciones de coenzima Q10 para tratar tumores sólidos mediante administración intravenosa |
| JPWO2008069276A1 (ja) * | 2006-12-06 | 2010-03-25 | 株式会社カネカ | 癌治療剤および発癌抑制剤 |
| CA2680825C (en) | 2007-03-22 | 2013-10-29 | Cytotech Labs, Llc | Topical formulations having enhanced bioavailability |
| CN103169973A (zh) * | 2007-11-12 | 2013-06-26 | 彼帕科学公司 | 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌 |
| WO2009082607A2 (en) | 2007-12-04 | 2009-07-02 | Alnylam Pharmaceuticals, Inc. | Targeting lipids |
| US8247435B2 (en) * | 2009-02-19 | 2012-08-21 | Thornthwaite Jerry T | Formulations for treating human and animal diseases |
| AU2010247800A1 (en) * | 2009-05-11 | 2011-12-15 | Berg Llc | Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers |
| GB0913193D0 (en) | 2009-07-29 | 2009-09-02 | Johnson Matthey Plc | Deoxygenation process |
| CN105168135A (zh) * | 2010-03-12 | 2015-12-23 | 博格有限责任公司 | 辅酶Q10(CoQ10)的静脉内制剂及其使用方法 |
| US10973763B2 (en) | 2011-06-17 | 2021-04-13 | Berg Llc | Inhalable pharmaceutical compositions |
| MX369768B (es) * | 2012-06-01 | 2019-11-21 | Berg Llc | Composición farmacéutica de coenzima q10 para usarse en un método para tratar cáncer. |
-
2013
- 2013-05-31 MX MX2014014492A patent/MX369768B/es active IP Right Grant
- 2013-05-31 IN IN10734DEN2014 patent/IN2014DN10734A/en unknown
- 2013-05-31 CA CA3090268A patent/CA3090268A1/en not_active Abandoned
- 2013-05-31 NZ NZ702369A patent/NZ702369A/en not_active IP Right Cessation
- 2013-05-31 SG SG11201407880QA patent/SG11201407880QA/en unknown
- 2013-05-31 CA CA2875150A patent/CA2875150C/en active Active
- 2013-05-31 EA EA201492187A patent/EA032345B1/ru not_active IP Right Cessation
- 2013-05-31 JP JP2015515272A patent/JP6352905B2/ja active Active
- 2013-05-31 BR BR112014029954A patent/BR112014029954A2/pt not_active IP Right Cessation
- 2013-05-31 CN CN201380040105.3A patent/CN104507308A/zh active Pending
- 2013-05-31 US US13/907,726 patent/US20140017317A1/en not_active Abandoned
- 2013-05-31 ES ES13797642T patent/ES2761449T3/es active Active
- 2013-05-31 WO PCT/US2013/043785 patent/WO2013181639A1/en not_active Ceased
- 2013-05-31 KR KR1020207028370A patent/KR20200118233A/ko not_active Ceased
- 2013-05-31 AU AU2013267166A patent/AU2013267166A1/en not_active Abandoned
- 2013-05-31 KR KR1020147037100A patent/KR102163948B1/ko active Active
- 2013-05-31 EP EP13797642.9A patent/EP2854528B8/en active Active
-
2014
- 2014-11-27 MX MX2019013776A patent/MX2019013776A/es unknown
- 2014-11-30 IL IL236008A patent/IL236008B/en active IP Right Grant
-
2016
- 2016-10-10 US US15/289,770 patent/US20170216223A1/en not_active Abandoned
-
2017
- 2017-04-19 AU AU2017202567A patent/AU2017202567B2/en not_active Ceased
-
2018
- 2018-06-07 JP JP2018109093A patent/JP2018168164A/ja not_active Withdrawn
-
2020
- 2020-07-29 JP JP2020127877A patent/JP7225167B2/ja active Active
-
2021
- 2021-05-17 US US17/321,699 patent/US20220096399A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020183440A5 (https=) | ||
| Böttger et al. | High-dose intravenous vitamin C, a promising multi-targeting agent in the treatment of cancer | |
| JP2015518056A5 (https=) | ||
| EP2488178B1 (en) | Combinations of a pi3k inhibitor and a mek inhibitor | |
| JP6648040B2 (ja) | がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用 | |
| Droz et al. | Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial | |
| US12083136B2 (en) | Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof | |
| TWI818954B (zh) | 三取代之苯并三唑衍生物的使用方法 | |
| Lin et al. | Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer | |
| JP2014513089A (ja) | アフリバーセプト、フォリン酸、５−フルオロウラシル（５−ｆｕ）及びイリノセタン（フォルフィリ）を含む組成物 | |
| US20240245704A1 (en) | Pharmaceutical composition and use of multi-kinase inhibitor | |
| Gatzemeier et al. | Tirapazamine-cisplatin: the synergy | |
| Mountzios et al. | Novel Approaches for Concurrent Irradiation in Locally Advanced Cervical Cancer: Platinum Combinations, Non‐Platinum‐Containing Regimens, and Molecular Targeted Agents | |
| TWI598095B (zh) | 治療或緩解高齡或末期癌症患者用之醫藥組合物 | |
| WO2020254299A1 (en) | Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof | |
| Said et al. | Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver | |
| CN101155600B (zh) | 放射线治疗增强剂 | |
| Kudo | Why does every hepatocellular carcinoma clinical trial using molecular targeted agents fail? | |
| Liu et al. | Etoposide sensitizes CT26 colorectal adenocarcinoma to radiation therapy in BALB/c mice | |
| Novello et al. | Use of chemo-radiotherapy in locally advanced non-small cell lung cancer | |
| Xue et al. | Anti-angiogenesis treatment in a patient with appendix metastasis of small cell lung cancer: A case report | |
| AU2006231809A1 (en) | Potentiator for radiation therapy comprising pyridine derivative as active ingredient | |
| Schwartz et al. | The addition of chloroquine and metformine to Metabloc induces a rapid drop of tumor markers in advanced carcinoma | |
| JPWO2022229907A5 (https=) | ||
| CN101155782A (zh) | 以吡啶衍生物为有效成分的放射线治疗增强剂 |